Save Product
Product Details
Synonyms
IGFBP3, BP-53, IBP3
Source
Human IGFBP-3, His Tag (IG3-H52H9) is expressed from human 293 cells (HEK293). It contains AA Gly 28 - Lys 291 (Accession # P17936-1).
Predicted N-terminus: Gly 28
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 30.6 kDa. The protein migrates as 40-50 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Human IGFBP-3, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
Bioactivity-ELISA
Immobilized Biotinylated Human IGF-II, Avitag,Fc Tag (Cat. No. IG2-H82F9) at 2 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (1 μg/well) plate can bind Human IGFBP-3, His Tag (Cat. No. IG3-H52H9) with a linear range of 0.01-0.313 μg/mL (QC tested).
Protocol
Immobilized Human IGFBP-3, His Tag (Cat. No. IG3-H52H9) at 5 μg/mL (100 μL/well) can bind Human IGF-I, Fc Tag with a linear range of 0.6-39 ng/mL (Routinely tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Drug Development Progress- English Name：
Insulin-like growth factor binding protein III
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
2 Details
- Highest Development Stage：
Phase 2 Clinical
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
